To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8857 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8857 To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES May 15, 2026 Mr. Morelle (for himself, Mr. Gottheimer, Mr. Pfluger, and Mr. Kean) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Next Generation Medicines Act of 2026'' or the ``Next GEN Act of 2026''. SEC. 2. ADJUSTING RULES FOR ENGINEERED CYCLIC PEPTIDES UNDER DRUG PRICE NEGOTIATION PROGRAM. (a) In General.--Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e)) is amended-- (1) in paragraph (1)(A)(ii), by inserting ``(or, in the case of an engineered cyclic peptide (as defined in paragraph (5)), 11 years)'' after ``7 years''; and (2) by adding at the end the following new paragraph: ``(5) Engineered cyclic peptide defined.--In this subsection, the term `engineered cyclic peptide' means a polymer that-- ``(A) is composed principally of amino acids; ``(B) contains not less than 1 cyclic structure produced through head-to-tail cyclization, head-to- si